http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2018, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 02 Nov 2017 02:31:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html for the full story. http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Thu, 02 Nov 2017 02:31:00 -0400 0O59 A.02264286 A.06598119 A.06822034 A.06924712 A.20111752 A.30801315 A.31161379 A.32670657 A.40470293 GENZ SAN SNY http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html for the full story. http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Thu, 02 Nov 2017 02:31:00 -0400 0O59 A.02264286 A.06598119 A.06822034 A.06924712 A.20111752 A.30801315 A.31161379 A.32670657 A.40470293 GENZ SAN SNY http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html for the full story. http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Thu, 02 Nov 2017 02:31:00 -0400 0O59 A.02264286 A.06598119 A.06822034 A.06924712 A.20111752 A.30801315 A.31161379 A.32670657 A.40470293 GENZ SAN SNY http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html for the full story. http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Thu, 02 Nov 2017 02:31:00 -0400 0O59 A.02264286 A.06598119 A.06822034 A.06924712 A.20111752 A.30801315 A.31161379 A.32670657 A.40470293 GENZ SAN SNY http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html for the full story. http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Thu, 02 Nov 2017 02:31:00 -0400 0O59 A.02264286 A.06598119 A.06822034 A.06924712 A.20111752 A.30801315 A.31161379 A.32670657 A.40470293 GENZ SAN SNY http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html for the full story. http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Thu, 02 Nov 2017 02:31:00 -0400 0O59 A.02264286 A.06598119 A.06822034 A.06924712 A.20111752 A.30801315 A.31161379 A.32670657 A.40470293 GENZ SAN SNY http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html for the full story. http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Thu, 02 Nov 2017 02:31:00 -0400 0O59 A.02264286 A.06598119 A.06822034 A.06924712 A.20111752 A.30801315 A.31161379 A.32670657 A.40470293 GENZ SAN SNY http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html for the full story. http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Thu, 02 Nov 2017 02:31:00 -0400 0O59 A.02264286 A.06598119 A.06822034 A.06924712 A.20111752 A.30801315 A.31161379 A.32670657 A.40470293 GENZ SAN SNY http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html for the full story. http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Thu, 02 Nov 2017 02:31:00 -0400 0O59 A.02264286 A.06598119 A.06822034 A.06924712 A.20111752 A.30801315 A.31161379 A.32670657 A.40470293 GENZ SAN SNY http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html for the full story. http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Thu, 02 Nov 2017 02:31:00 -0400 0O59 A.02264286 A.06598119 A.06822034 A.06924712 A.20111752 A.30801315 A.31161379 A.32670657 A.40470293 GENZ SAN SNY http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html for the full story. http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Thu, 02 Nov 2017 02:31:00 -0400 0O59 A.02264286 A.06598119 A.06822034 A.06924712 A.20111752 A.30801315 A.31161379 A.32670657 A.40470293 GENZ SAN SNY http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html for the full story. http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Thu, 02 Nov 2017 02:31:00 -0400 0O59 A.02264286 A.06598119 A.06822034 A.06924712 A.20111752 A.30801315 A.31161379 A.32670657 A.40470293 GENZ SAN SNY http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html for the full story. http://www.streetinsider.com/Press+Releases/Sanofi+%3A+Q3+2017+Business+EPS+up+1.1%25+at+CER+FY+2017+Guidance+Confirmed/13455709.html Thu, 02 Nov 2017 02:31:00 -0400 0O59 A.02264286 A.06598119 A.06822034 A.06924712 A.20111752 A.30801315 A.31161379 A.32670657 A.40470293 GENZ SAN SNY http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Report+Positive+Topline+Results+from+APOLLO+Phase+3+Study+of+Patisiran+in+Hereditary+ATTR+%28hATTR%29+Amyloidosis+Patients+with+Polyneuropathy/13312025.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Report+Positive+Topline+Results+from+APOLLO+Phase+3+Study+of+Patisiran+in+Hereditary+ATTR+%28hATTR%29+Amyloidosis+Patients+with+Polyneuropathy/13312025.html for the full story. http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Report+Positive+Topline+Results+from+APOLLO+Phase+3+Study+of+Patisiran+in+Hereditary+ATTR+%28hATTR%29+Amyloidosis+Patients+with+Polyneuropathy/13312025.html Wed, 20 Sep 2017 07:00:00 -0400 0O59 A.02264286 A.06822034 ALNY GENZ SAN SNY http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Report+Positive+Topline+Results+from+APOLLO+Phase+3+Study+of+Patisiran+in+Hereditary+ATTR+%28hATTR%29+Amyloidosis+Patients+with+Polyneuropathy/13312025.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Report+Positive+Topline+Results+from+APOLLO+Phase+3+Study+of+Patisiran+in+Hereditary+ATTR+%28hATTR%29+Amyloidosis+Patients+with+Polyneuropathy/13312025.html for the full story. http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Report+Positive+Topline+Results+from+APOLLO+Phase+3+Study+of+Patisiran+in+Hereditary+ATTR+%28hATTR%29+Amyloidosis+Patients+with+Polyneuropathy/13312025.html Wed, 20 Sep 2017 07:00:00 -0400 0O59 A.02264286 A.06822034 ALNY GENZ SAN SNY http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Report+Positive+Topline+Results+from+APOLLO+Phase+3+Study+of+Patisiran+in+Hereditary+ATTR+%28hATTR%29+Amyloidosis+Patients+with+Polyneuropathy/13312025.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Report+Positive+Topline+Results+from+APOLLO+Phase+3+Study+of+Patisiran+in+Hereditary+ATTR+%28hATTR%29+Amyloidosis+Patients+with+Polyneuropathy/13312025.html for the full story. http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Report+Positive+Topline+Results+from+APOLLO+Phase+3+Study+of+Patisiran+in+Hereditary+ATTR+%28hATTR%29+Amyloidosis+Patients+with+Polyneuropathy/13312025.html Wed, 20 Sep 2017 07:00:00 -0400 0O59 A.02264286 A.06822034 ALNY GENZ SAN SNY http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Report+Positive+Topline+Results+from+APOLLO+Phase+3+Study+of+Patisiran+in+Hereditary+ATTR+%28hATTR%29+Amyloidosis+Patients+with+Polyneuropathy/13312025.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Report+Positive+Topline+Results+from+APOLLO+Phase+3+Study+of+Patisiran+in+Hereditary+ATTR+%28hATTR%29+Amyloidosis+Patients+with+Polyneuropathy/13312025.html for the full story. http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Report+Positive+Topline+Results+from+APOLLO+Phase+3+Study+of+Patisiran+in+Hereditary+ATTR+%28hATTR%29+Amyloidosis+Patients+with+Polyneuropathy/13312025.html Wed, 20 Sep 2017 07:00:00 -0400 0O59 A.02264286 A.06822034 ALNY GENZ SAN SNY http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Report+Positive+Topline+Results+from+APOLLO+Phase+3+Study+of+Patisiran+in+Hereditary+ATTR+%28hATTR%29+Amyloidosis+Patients+with+Polyneuropathy/13312025.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Report+Positive+Topline+Results+from+APOLLO+Phase+3+Study+of+Patisiran+in+Hereditary+ATTR+%28hATTR%29+Amyloidosis+Patients+with+Polyneuropathy/13312025.html for the full story. http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Report+Positive+Topline+Results+from+APOLLO+Phase+3+Study+of+Patisiran+in+Hereditary+ATTR+%28hATTR%29+Amyloidosis+Patients+with+Polyneuropathy/13312025.html Wed, 20 Sep 2017 07:00:00 -0400 0O59 A.02264286 A.06822034 ALNY GENZ SAN SNY http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Report+Positive+Topline+Results+from+APOLLO+Phase+3+Study+of+Patisiran+in+Hereditary+ATTR+%28hATTR%29+Amyloidosis+Patients+with+Polyneuropathy/13312025.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Report+Positive+Topline+Results+from+APOLLO+Phase+3+Study+of+Patisiran+in+Hereditary+ATTR+%28hATTR%29+Amyloidosis+Patients+with+Polyneuropathy/13312025.html for the full story. http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Report+Positive+Topline+Results+from+APOLLO+Phase+3+Study+of+Patisiran+in+Hereditary+ATTR+%28hATTR%29+Amyloidosis+Patients+with+Polyneuropathy/13312025.html Wed, 20 Sep 2017 07:00:00 -0400 0O59 A.02264286 A.06822034 ALNY GENZ SAN SNY http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Report+Positive+Topline+Results+from+APOLLO+Phase+3+Study+of+Patisiran+in+Hereditary+ATTR+%28hATTR%29+Amyloidosis+Patients+with+Polyneuropathy/13312025.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Report+Positive+Topline+Results+from+APOLLO+Phase+3+Study+of+Patisiran+in+Hereditary+ATTR+%28hATTR%29+Amyloidosis+Patients+with+Polyneuropathy/13312025.html for the full story. http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Report+Positive+Topline+Results+from+APOLLO+Phase+3+Study+of+Patisiran+in+Hereditary+ATTR+%28hATTR%29+Amyloidosis+Patients+with+Polyneuropathy/13312025.html Wed, 20 Sep 2017 07:00:00 -0400 0O59 A.02264286 A.06822034 ALNY GENZ SAN SNY http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Genzyme+Report+Positive+Results+from+Ongoing+Phase+2+Open-Label+Extension+Study+with+Investigational+RNAi+Therapeutic+Fitusiran+in+Patients+with+Hemophilia+A+and+B+With+or+Without+I/13083183.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Genzyme+Report+Positive+Results+from+Ongoing+Phase+2+Open-Label+Extension+Study+with+Investigational+RNAi+Therapeutic+Fitusiran+in+Patients+with+Hemophilia+A+and+B+With+or+Without+I/13083183.html for the full story. http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Genzyme+Report+Positive+Results+from+Ongoing+Phase+2+Open-Label+Extension+Study+with+Investigational+RNAi+Therapeutic+Fitusiran+in+Patients+with+Hemophilia+A+and+B+With+or+Without+I/13083183.html Mon, 10 Jul 2017 09:30:00 -0400 0O59 A.02264286 A.06822034 A.09649487 ALNY GENZ SAN SNY http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Genzyme+Report+Positive+Results+from+Ongoing+Phase+2+Open-Label+Extension+Study+with+Investigational+RNAi+Therapeutic+Fitusiran+in+Patients+with+Hemophilia+A+and+B+With+or+Without+I/13083183.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Genzyme+Report+Positive+Results+from+Ongoing+Phase+2+Open-Label+Extension+Study+with+Investigational+RNAi+Therapeutic+Fitusiran+in+Patients+with+Hemophilia+A+and+B+With+or+Without+I/13083183.html for the full story. http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Genzyme+Report+Positive+Results+from+Ongoing+Phase+2+Open-Label+Extension+Study+with+Investigational+RNAi+Therapeutic+Fitusiran+in+Patients+with+Hemophilia+A+and+B+With+or+Without+I/13083183.html Mon, 10 Jul 2017 09:30:00 -0400 0O59 A.02264286 A.06822034 A.09649487 ALNY GENZ SAN SNY http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Genzyme+Report+Positive+Results+from+Ongoing+Phase+2+Open-Label+Extension+Study+with+Investigational+RNAi+Therapeutic+Fitusiran+in+Patients+with+Hemophilia+A+and+B+With+or+Without+I/13083183.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Genzyme+Report+Positive+Results+from+Ongoing+Phase+2+Open-Label+Extension+Study+with+Investigational+RNAi+Therapeutic+Fitusiran+in+Patients+with+Hemophilia+A+and+B+With+or+Without+I/13083183.html for the full story. http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Genzyme+Report+Positive+Results+from+Ongoing+Phase+2+Open-Label+Extension+Study+with+Investigational+RNAi+Therapeutic+Fitusiran+in+Patients+with+Hemophilia+A+and+B+With+or+Without+I/13083183.html Mon, 10 Jul 2017 09:30:00 -0400 0O59 A.02264286 A.06822034 A.09649487 ALNY GENZ SAN SNY http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Genzyme+Report+Positive+Results+from+Ongoing+Phase+2+Open-Label+Extension+Study+with+Investigational+RNAi+Therapeutic+Fitusiran+in+Patients+with+Hemophilia+A+and+B+With+or+Without+I/13083183.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Genzyme+Report+Positive+Results+from+Ongoing+Phase+2+Open-Label+Extension+Study+with+Investigational+RNAi+Therapeutic+Fitusiran+in+Patients+with+Hemophilia+A+and+B+With+or+Without+I/13083183.html for the full story. http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Genzyme+Report+Positive+Results+from+Ongoing+Phase+2+Open-Label+Extension+Study+with+Investigational+RNAi+Therapeutic+Fitusiran+in+Patients+with+Hemophilia+A+and+B+With+or+Without+I/13083183.html Mon, 10 Jul 2017 09:30:00 -0400 0O59 A.02264286 A.06822034 A.09649487 ALNY GENZ SAN SNY http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Genzyme+Report+Positive+Results+from+Ongoing+Phase+2+Open-Label+Extension+Study+with+Investigational+RNAi+Therapeutic+Fitusiran+in+Patients+with+Hemophilia+A+and+B+With+or+Without+I/13083183.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Genzyme+Report+Positive+Results+from+Ongoing+Phase+2+Open-Label+Extension+Study+with+Investigational+RNAi+Therapeutic+Fitusiran+in+Patients+with+Hemophilia+A+and+B+With+or+Without+I/13083183.html for the full story. http://www.streetinsider.com/Press+Releases/Alnylam+and+Sanofi+Genzyme+Report+Positive+Results+from+Ongoing+Phase+2+Open-Label+Extension+Study+with+Investigational+RNAi+Therapeutic+Fitusiran+in+Patients+with+Hemophilia+A+and+B+With+or+Without+I/13083183.html Mon, 10 Jul 2017 09:30:00 -0400 0O59 A.02264286 A.06822034 A.09649487 ALNY GENZ SAN SNY